MAP2K7 and melanoma: Additionally, targeted therapies approved for the treatment of BRAF V600–altered melanoma include BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) and MEK inhibitors (trametinib, combimetinib, binimetinib).